AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ANTX AN2 Therapeutics, Inc.

休市中 02-27 16:00:00 EST

1.10

+0.04

+3.77%

盘后1.10

+0.000.00%

16:04 EST

最高1.11	最低1.06	成交量4.58万
今开1.07	昨收1.06	日振幅5.19%
总市值3,014万	流通市值2,108万	总股本2,740万
成交额4.97万	换手率0.24%	流通股本1,916万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ANTX","market":"US","secType":"STK","nameCN":"AN2 Therapeutics, Inc.","latestPrice":1.1,"timestamp":1772226000000,"preClose":1.06,"halted":0,"volume":45792,"hourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"16:04 EST","volume":1,"amount":1.1,"timestamp":1772226241462,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03773584905660381,"floatShares":19164900,"shares":27402024,"eps":-1.129215,"marketStatus":"休市中","change":0.04,"latestTime":"02-27 16:00:00 EST","open":1.07,"high":1.11,"low":1.055,"amount":49716.859795,"amplitude":0.051887,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.129215,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1648180800000,"exchange":"NASDAQ","adjPreClose":1.06,"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"16:04 EST","volume":1,"amount":1.1,"timestamp":1772226241462,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5486161187517371},"requestUrl":"/m/hq/s/ANTX","defaultTab":"news","newsList":[{"id":"1194179960","title":"AN2 Therapeutics获FDA批准开展Epetraborole针对脓肿分枝杆菌肺病90人研究者启动试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194179960","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194179960?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219347,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics, Inc.宣布，其药品Epetraborole用于治疗脓肿分枝杆菌肺病的90人规模研究者启动试验（IIT）已获得美国食品药品监督管理局（FDA）的批准，可继续进行。\n该试验将由研究者主导，旨在评估Epetraborole在特定患者群体中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2582936115","title":"AN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2582936115","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582936115?lang=zh_cn&edition=full","pubTime":"2025-11-11 14:19","pubTimestamp":1762841940,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis .AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病的新疗法。经验证的LeuRS靶点是多种化合物的基础，包括用于治疗NTM肺病的在研药物epetraborole、用于治疗结核病的在研药物ganfeborole，以及获得FDA批准的抗真菌药物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.这项合作建立在AN2团队与GSK全球健康研发小组之前的工作基础之上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK","LU1829250122.USD","BK4139","BK4539","LENZ","BK4585","BK4007","BK4588","GSK.UK","BK4532","ANTX"],"gpt_icon":0},{"id":"1177296647","title":"AN2 Therapeutics与GSK达成研究合作，推进针对结核病的硼基Leurs抑制剂研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1177296647","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177296647?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776111,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics与GSK达成研究合作，推进针对结核病的硼基Leurs抑制剂研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2514016181","title":"Citizens Capital Markets：重申AN2 Therapeutics(ANTX.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016181","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514016181?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:41","pubTimestamp":1740498087,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申AN2 Therapeutics(ANTX.US)评级，由优于大市调整至优于大市评级, 目标价由5.00美元调整至5.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25234148384500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","ANTX"],"gpt_icon":0},{"id":"2490633608","title":"An2 Therapeutics, Inc.盘中异动 急速拉升5.30%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490633608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490633608?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:36","pubTimestamp":1733927805,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时36分，An2 Therapeutics, Inc.股票出现异动，股价大幅拉升5.30%。截至发稿，该股报1.59美元/股，成交量5.2028万股，换手率0.17%，振幅2.65%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121122364695e8f857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121122364695e8f857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ANTX"],"gpt_icon":0},{"id":"2490011590","title":"An2 Therapeutics, Inc.盘中异动 早盘急速上涨5.63%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490011590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490011590?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:35","pubTimestamp":1733841334,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时35分，An2 Therapeutics, Inc.股票出现异动，股价快速上涨5.63%。截至发稿，该股报1.50美元/股，成交量7061股，换手率0.02%，振幅4.23%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223534984b0c1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223534984b0c1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ANTX","LENZ"],"gpt_icon":0},{"id":"2488924925","title":"An2 Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488924925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488924925?lang=zh_cn&edition=full","pubTime":"2024-12-04 02:21","pubTimestamp":1733250109,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日02时21分，An2 Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。截至发稿，该股报1.52美元/股，成交量8.9225万股，换手率0.30%，振幅4.38%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.64%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120402214998e52592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120402214998e52592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","ANTX"],"gpt_icon":0},{"id":"2488729966","title":"An2 Therapeutics, Inc.盘中异动 急速下挫5.99%报1.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488729966","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488729966?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:33","pubTimestamp":1733150032,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时33分，An2 Therapeutics, Inc.股票出现异动，股价快速跳水5.99%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Senti Biosciences, Inc.、Purple Biotech Ltd、Revelation Biosciences, Inc.较为活跃，换手率分别为724.43%、690.02%、204.07%，振幅较大的相关个股有Senti Biosciences, Inc.、Purple Biotech Ltd、Renovaro Inc.，振幅分别为49.54%、20.27%、17.49%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223352971b2e16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223352971b2e16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ANTX","LENZ","BK4007"],"gpt_icon":0},{"id":"2487954550","title":"An2 Therapeutics, Inc.盘中异动 股价大涨8.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487954550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487954550?lang=zh_cn&edition=full","pubTime":"2024-11-29 22:30","pubTimestamp":1732890623,"startTime":"0","endTime":"0","summary":"北京时间2024年11月29日22时30分，An2 Therapeutics, Inc.股票出现异动，股价急速拉升8.03%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Cabaletta Bio, Inc.、Passage Bio, Inc.、Pyxis Oncology, Inc.涨幅较大，Silo Pharma, Inc.、Tc Biopharm  Plc、Applied Therapeutics, Inc.较为活跃，换手率分别为133.69%、11.55%、7.12%，振幅较大的相关个股有Os Therapies Incorporated、Cero Therapeutics Holdings, Inc.、Gyre Therapeutics, Inc.，振幅分别为6.31%、5.44%、2.46%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223023971aa629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129223023971aa629&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ANTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2486284080","title":"An2 Therapeutics, Inc.盘中异动 股价大涨5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486284080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486284080?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:37","pubTimestamp":1732545454,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时37分，An2 Therapeutics, Inc.股票出现异动，股价大幅上涨5.97%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223734971a85e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223734971a85e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","ANTX"],"gpt_icon":0},{"id":"2485932552","title":"An2 Therapeutics, Inc.2024财年第三财季实现净利润-12.75百万美元，同比增加23.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485932552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485932552?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:00","pubTimestamp":1732291249,"startTime":"0","endTime":"0","summary":"11月23日，An2 Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-12.75百万美元，同比增加23.70%；其中营业收入为0.00美元，每股基本收益为-0.43美元。机构评级：截至2024年11月23日，当前有3家机构对An2 Therapeutics, Inc.目标价做出预测，其中目标均价为2.67美元，其中最低目标价为1.00美元，最高目标价为5.00美元。公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000102a24e4863&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000102a24e4863&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANTX","LENZ"],"gpt_icon":0},{"id":"2485261379","title":"An2 Therapeutics, Inc.盘中异动 快速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261379?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:31","pubTimestamp":1732285874,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时31分，An2 Therapeutics, Inc.股票出现异动，股价急速拉升5.37%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Virpax Pharmaceuticals, Inc.、Exicure, Inc.、Replimune Group, Inc.涨幅较大，Virpax Pharmaceuticals, Inc.、Molecular Templates, Inc.、Exicure, Inc.较为活跃，换手率分别为499.28%、61.77%、35.49%，振幅较大的相关个股有Exicure, Inc.、Virpax Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为10.96%、9.21%、9.19%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122223114abd7918d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122223114abd7918d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ANTX"],"gpt_icon":0},{"id":"2477886375","title":"An2 Therapeutics, Inc.盘中异动 早盘股价大涨5.71%报1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477886375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477886375?lang=zh_cn&edition=full","pubTime":"2024-10-21 21:34","pubTimestamp":1729517659,"startTime":"0","endTime":"0","summary":"北京时间2024年10月21日21时34分，An2 Therapeutics, Inc.股票出现波动，股价快速拉升5.71%。截至发稿，该股报1.11美元/股，成交量11.0649万股，换手率0.37%，振幅3.75%。An2 Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。An2 Therapeutics, Inc.公司简介：AN2 Therapeutics Inc是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的药物，这些疾病的需求未得到满足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021213419a1e24972&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021213419a1e24972&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","ANTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.an2therapeutics.com","stockEarnings":[{"period":"1week","weight":0.0577},{"period":"1month","weight":-0.0756},{"period":"3month","weight":0.0092},{"period":"6month","weight":0},{"period":"1year","weight":-0.009},{"period":"ytd","weight":-0.0351}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AN2 Therapeutics, Inc.于2017年2月在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，开发治疗罕见、慢性和严重传染病的治疗方法，这些疾病的需求未得到满足。该公司的初步候选药物是epetraborole，该公司正在研究将其作为一种潜在的每日一次、具有新型作用机制的口服治疗药物，用于非结核分枝杆菌（“NTM”）肺部疾病患者，这是一种罕见的、慢性和进行性传染病，由称为分枝杆菌的细菌引起，可导致不可逆的肺部损伤并可能致命。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.008802},{"month":2,"riseRate":0,"avgChangeRate":-0.236128},{"month":3,"riseRate":0.666667,"avgChangeRate":0.052862},{"month":4,"riseRate":0.25,"avgChangeRate":-0.129319},{"month":5,"riseRate":0,"avgChangeRate":-0.160413},{"month":6,"riseRate":0.5,"avgChangeRate":0.028055},{"month":7,"riseRate":0.5,"avgChangeRate":0.061464},{"month":8,"riseRate":0.75,"avgChangeRate":0.333856},{"month":9,"riseRate":0.75,"avgChangeRate":0.04615},{"month":10,"riseRate":0.25,"avgChangeRate":-0.073924},{"month":11,"riseRate":0.5,"avgChangeRate":0.085581},{"month":12,"riseRate":0.5,"avgChangeRate":-0.00143}],"exchange":"NASDAQ","name":"AN2 Therapeutics, Inc.","nameEN":"AN2 Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AN2 Therapeutics, Inc.(ANTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AN2 Therapeutics, Inc.,ANTX,AN2 Therapeutics, Inc.股票,AN2 Therapeutics, Inc.股票老虎,AN2 Therapeutics, Inc.股票老虎国际,AN2 Therapeutics, Inc.行情,AN2 Therapeutics, Inc.股票行情,AN2 Therapeutics, Inc.股价,AN2 Therapeutics, Inc.股市,AN2 Therapeutics, Inc.股票价格,AN2 Therapeutics, Inc.股票交易,AN2 Therapeutics, Inc.股票购买,AN2 Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AN2 Therapeutics, Inc.(ANTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AN2 Therapeutics, Inc.(ANTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}